And per this article I posted yesterday…
Yes you will see Mr Stevens below also presenting at the Cannabis Europa conference
Here’s his pitch at the end of his piece
Here’s a duly sycophantic introduction to the great lords of cannabis!
In a way I’m hoping he just re-published what Curaleaf’s PR people sent him.
It would almost be worse if he actually wrote this gumph.
Curaleaf International is already one of the most prominent cannabis companies in the world, with a presence in the UK, Germany, France, Italy, Switzerland, Spain, Portugal, Poland and the Czech Republic.
Despite its significant existing global footprint, the company has had a busy start to the year, seeing a near 60% growth in revenues over the first quarter, as it continues to make strategic acquisitions to bolster its position in the flourishing European medical market.
Ahead of Cannabis Europa next week, where Curaleaf’s Executive Chairman, Boris Jordan, Curaleaf International’s Managing Director of the UK & Nordics, Jonathan Hodgson, and the head of Curaleaf International, Juan Martinez, will be speaking, we caught up with Juan to discuss the company’s progress in Europe and what he expects for the future of the rapidly growing market.
BofC: Curaleaf International has had a busy start to 2024, can you give us an overview of your activities throughout Europe so far this year?
Juan Martinez: It’s been a fantastic start to the year for us at Curaleaf. Our international business saw a 59% year-over-year revenue growth in the first quarter, thanks to the strong medical cannabis markets in our key regions such as the UK, Germany, and Poland. We’ve also been building brand awareness in emerging markets like Switzerland, Czechia, and Sweden.
We kicked off the year with a really positive rebrand of our UK clinic from Sapphire Clinics to Curaleaf Clinics. The UK has also seen strong patient reception to our expanding product offering including pastilles and vapes.
In February, we completed the acquisition of Can4Med, a major pharmaceutical wholesaler in Poland. With a population of 38 million people, Poland is proving to be a strong market for us as the country is witnessing a political and societal shift towards cannabis increasingly accepted as a medicine by patients and doctors alike.
To further bolster our position in Europe, in late March, we announced the acquisition of Northern Green Canada, an EU-GMP certified producer of high-quality indoor flower. Not only is NGC transaction accretive to our international gross margins, but it also ensures the stability of our supply chain into Europe. An added benefit from this transaction is the ability to study 2 other high-growth medical cannabis markets NGC currently sells into, Australia and New Zealand. This acquisition represents another key pillar in the development of our global brand strategy.
and so on and so forth
read it all at
